Alexandre Karras

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3868346/publications.pdf

Version: 2024-02-01

50273 53222 8,021 151 46 85 citations h-index g-index papers 158 158 158 8016 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. New England Journal of Medicine, 2014, 371, 1771-1780.	27.0	842
2	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney International, 2012, 82, 454-464.	5.2	454
3	Tenofovirâ€Related Nephrotoxicity in Human Immunodeficiency Virus–Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus. Clinical Infectious Diseases, 2003, 36, 1070-1073.	5 . 8	339
4	Rituximab plus Peg-interferon-α/ribavirin compared with Peg-interferon-α/ribavirin in hepatitis C–related mixed cryoglobulinemia. Blood, 2010, 116, 326-334.	1.4	248
5	<i>INF2</i> Mutations in Charcot–Marie–Tooth Disease with Glomerulopathy. New England Journal of Medicine, 2011, 365, 2377-2388.	27.0	235
6	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Annals of the Rheumatic Diseases, 2018, 77, 1143-1149.	0.9	219
7	Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation, 2004, 77, 238-243.	1.0	166
8	Large Artery Stiffening and Remodeling Are Independently Associated With All-Cause Mortality and Cardiovascular Events in Chronic Kidney Disease. Hypertension, 2012, 60, 1451-1457.	2.7	161
9	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2017, 76, 1662-1668.	0.9	159
10	Rituximab in Severe Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 579-587.	4.5	151
11	The Spectrum of Type I Cryoglobulinemia Vasculitis. Medicine (United States), 2013, 92, 61-68.	1.0	150
12	Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 50-59.	4.5	148
13	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. Journal of Antimicrobial Chemotherapy, 2010, 65, 2628-2640.	3.0	141
14	Mutations in INF2 Are a Major Cause of Autosomal Dominant Focal Segmental Glomerulosclerosis. Journal of the American Society of Nephrology: JASN, 2011, 22, 239-245.	6.1	138
15	Arterial Remodeling Associates with CKD Progression. Journal of the American Society of Nephrology: JASN, 2011, 22, 967-974.	6.1	135
16	Acute Renal Infarction. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 392-398.	4.5	135
17	Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy–associated C3 glomerulopathy. Blood, 2017, 129, 1437-1447.	1.4	120
18	Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy. JAMA - Journal of the American Medical Association, 2017, 318, 2099.	7.4	120

#	Article	IF	Citations
19	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Annals of Internal Medicine, 2020, 173, 179-187.	3.9	116
20	A Clinicopathologic Study of Thrombotic Microangiopathy in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 137-148.	6.1	115
21	Patterns of Noncryoglobulinemic Glomerulonephritis with Monoclonal Ig Deposits. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1609-1616.	4.5	114
22	Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney International, 2011, 79, 643-654.	5.2	108
23	Efficacy and tolerability of rituximab with or without PEGylated interferon alfaâ€2b plus ribavirin in severe hepatitis C virus–related vasculitis: A longâ€term followup study of thirtyâ€two patients. Arthritis and Rheumatism, 2009, 60, 2531-2540.	6.7	99
24	Association of Kidney Function, Vitamin D Deficiency, and Circulating Markers of Mineral and Bone Disorders in CKD. American Journal of Kidney Diseases, 2011, 58, 544-553.	1.9	97
25	Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. Journal of Clinical Virology, 2006, 35, 257-263.	3.1	95
26	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney International, 2017, 92, 1232-1241.	5.2	93
27	Renal and thymic pathology in thymoma-associated nephropathy: report of 21 cases and review of the literature. Nephrology Dialysis Transplantation, 2005, 20, 1075-1082.	0.7	89
28	PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Journal of Hepatology, 2015, 62, 24-30.	3.7	86
29	Rituximab in anti-GBM disease: A retrospective study of 8 patients. Journal of Autoimmunity, 2015, 60, 74-79.	6.5	84
30	High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney International, 2015, 88, 386-395.	5.2	84
31	Long-term Kidney Disease Outcomes in Fibrillary Glomerulonephritis: A Case Series of 27 Patients. American Journal of Kidney Diseases, 2013, 62, 679-690.	1.9	75
32	Insights From the Use in Clinical Practice of Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 Cases. American Journal of Kidney Diseases, 2014, 63, 40-48.	1.9	74
33	Atypical and secondary hemolytic uremic syndromes have a distinct presentation andÂnoÂcommon genetic risk factors. Kidney International, 2019, 95, 1443-1452.	5.2	74
34	Observations of a large Dent disease cohort. Kidney International, 2016, 90, 430-439.	5.2	71
35	Oxalate Nephropathy Associated with Chronic Pancreatitis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1895-1902.	4.5	70
36	Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies. Kidney International, 2011, 79, 635-642.	5.2	67

#	Article	IF	Citations
37	Mutation Update of the <i>CLCN5 </i> Gene Responsible for Dent Disease 1. Human Mutation, 2015, 36, 743-752.	2.5	66
38	Renal involvement in monoclonal (type I) cryoglobulinemia: Two cases associated with IgG3 \hat{I}^2 cryoglobulin. American Journal of Kidney Diseases, 2002, 40, 1091-1096.	1.9	65
39	Rapamycin-induced oligospermia. Transplantation, 2003, 76, 885-886.	1.0	63
40	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Medicale, 2013, 42, 1317-1330.	1.9	62
41	Timing and Determinants of Erythropoietin Deficiency in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 35-42.	4.5	60
42	Performance of GFR Estimating Equations in African Europeans: Basis for a Lower Race-Ethnicity Factor Than in African Americans. American Journal of Kidney Diseases, 2013, 62, 182-184.	1.9	60
43	Aortic Stiffness of Kidney Transplant Recipients Correlates with Donor Age. Journal of the American Society of Nephrology: JASN, 2008, 19, 798-805.	6.1	58
44	ANCA-associated vasculitis in patients with primary Sj \tilde{A} ¶gren's syndrome: Detailed analysis of 7 new cases and systematic literature review. Autoimmunity Reviews, 2015, 14, 742-750.	5.8	52
45	Successful Renal Retransplantation after Post-Transplant Lymphoproliferative Disease. American Journal of Transplantation, 2004, 4, 1904-1909.	4.7	51
46	Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis. Nature Communications, 2017, 8, 1829.	12.8	50
47	Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leukemia and Lymphoma, 2013, 54, 767-777.	1.3	49
48	A Variant of Peptide Transporter 2 Predicts the Severity of Porphyria-Associated Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 1924-1932.	6.1	46
49	What nephrologists need to know about hemophagocytic syndrome. Nature Reviews Nephrology, 2009, 5, 329-336.	9.6	44
50	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 1213-1224.	6.1	44
51	Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrology Dialysis Transplantation, 2012, 27, 1924-1930.	0.7	43
52	Presentation and Prognosis of Cardiac Involvement in Hepatitis C Virus-Related Vasculitis. American Journal of Cardiology, 2013, 111, 265-272.	1.6	43
53	Porphyria and kidney diseases. CKJ: Clinical Kidney Journal, 2018, 11, 191-197.	2.9	43
54	Excessive interleukin-15 transpresentation endows NKG2D+CD4+ T cells with innate-like capacity to lyse vascular endothelium in granulomatosis with polyangiitis (Wegener's). Arthritis and Rheumatism, 2011, 63, 2116-2126.	6.7	42

#	Article	IF	CITATIONS
55	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Frontiers in Immunology, 2018, 9, 2260.	4.8	42
56	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.8	39
57	A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. Rheumatology, 2017, 56, kew376.	1.9	38
58	Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated Receptor Î ³ Essential for Resistance to Crescentic GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 172-188.	6.1	38
59	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. Nephrology Dialysis Transplantation, 2017, 33, 1579-1590.	0.7	37
60	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. Autoimmunity Reviews, 2020, 19, 102671.	5.8	37
61	COVID-19–Related Collapsing Glomerulopathy in a Kidney Transplant Recipient. American Journal of Kidney Diseases, 2020, 76, 590-594.	1.9	37
62	Nephronophthisis related to homozygous NPHP1 gene deletion as a cause of chronic renal failure in adults. Nephrology Dialysis Transplantation, 2006, 21, 2660-2663.	0.7	36
63	Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. CKJ: Clinical Kidney Journal, 2016, 10, sfw101.	2.9	36
64	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. Journal of Autoimmunity, 2015, 65, 49-55.	6.5	34
65	Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. Nephrology Dialysis Transplantation, 2018, 33, 1661-1668.	0.7	32
66	Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease. Kidney International, 2019, 96, 1020-1029.	5.2	32
67	Proteomic analysis of neutrophils in ANCA-associated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1 involved in apoptotic cell clearance. Kidney International, 2019, 96, 397-408.	5.2	32
68	Urinary Retinol Binding Protein Is a Marker of the Extent of Interstitial Kidney Fibrosis. PLoS ONE, 2014, 9, e84708.	2.5	32
69	Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. Nephrology Dialysis Transplantation, 2014, 29, 1894-1902.	0.7	29
70	Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 514-521.	4.5	29
71	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. Rheumatology, 2021, 60, 359-365.	1.9	27
72	Ifosfamide nephrotoxicity in adult patients. CKJ: Clinical Kidney Journal, 2020, 13, 660-665.	2.9	26

#	Article	IF	CITATIONS
73	Microscopic Polyangiitis: New Insights into Pathogenesis, Clinical Features and Therapy. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 459-464.	2.1	25
74	Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. Journal of Autoimmunity, 2020, 112, 102467.	6.5	25
75	Reversal of Arterial Stiffness and Maladaptative Arterial Remodeling After Kidney Transplantation. Journal of the American Heart Association, 2017, 6, .	3.7	24
76	Fasting Urinary Osmolality, CKD Progression, and Mortality: AÂProspective Observational Study. American Journal of Kidney Diseases, 2019, 73, 596-604.	1.9	24
77	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. Journal of Clinical Oncology, 2020, 38, 2647-2657.	1.6	24
78	Reappraisal of Renal Arteritis in ANCA-associated Vasculitis: Clinical Characteristics, Pathology, and Outcome. Journal of the American Society of Nephrology: JASN, 2021, 32, 2362-2374.	6.1	24
79	Renal Function Decline Under Therapy With Small Interfering RNA Silencing ALAS1 for Acute Intermittent Porphyria. Kidney International Reports, 2021, 6, 1904-1911.	0.8	24
80	Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrology, 2021, 22, 267.	1.8	24
81	COMPLICATIONS OF PROTOCOL RENAL BIOPSY. Transplantation, 2004, 77, 1475-1476.	1.0	23
82	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. Seminars in Arthritis and Rheumatism, 2021, 51, 339-346.	3.4	22
83	Rituximab Treatment for Membranous Nephropathy: A French Clinical and Serological Retrospective Study of 28 Patients. Nephron Extra, 2011, 1, 251-261.	1.1	20
84	An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). Kidney International, 2018, 94, 1217-1226.	5.2	20
85	Confirmation of the low clinical effect of human herpesvirusâ€6 and â€7 infections after renal transplantation. Journal of Medical Virology, 2012, 84, 450-456.	5.0	19
86	Rule-Mining for the Early Prediction of Chronic Kidney Disease Based on Metabolomics and Multi-Source Data. PLoS ONE, 2016, 11, e0166905.	2.5	19
87	Tissue-Specific Microvascular Endothelial Cells Show Distinct Capacity To Activate NK Cells: Implications for the Pathophysiology of Granulomatosis with Polyangiitis. Journal of Immunology, 2014, 192, 3399-3408.	0.8	18
88	Specific changes in faecal microbiota are associated with familial Mediterranean fever. Annals of the Rheumatic Diseases, 2019, 78, 1398-1404.	0.9	18
89	Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. Nephrology Dialysis Transplantation, 2021, 36, 609-617.	0.7	18
90	Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. JAMA Network Open, 2022, 5, e2220925.	5.9	18

#	Article	IF	CITATIONS
91	Extracellular Fluid Volume Is an Independent Determinant of Uncontrolled and Resistant Hypertension in Chronic Kidney Disease: A NephroTest Cohort Study. Journal of the American Heart Association, 2018, 7, e010278.	3.7	17
92	Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 519-530.	3.1	16
93	Urinary Angiogenin Reflects the Magnitude of Kidney Injury at the Infrahistologic Level. Journal of the American Society of Nephrology: JASN, 2017, 28, 678-690.	6.1	15
94	Survival and specific outcome of sickle cell disease patients after renal transplantation. British Journal of Haematology, 2019, 187, 676-680.	2.5	15
95	Cardiovascular risk associated with high sodium-containing drugs: A systematic review. PLoS ONE, 2017, 12, e0180634.	2.5	13
96	Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 964-972.	4.5	13
97	APOL1 risk genotype in European steroid-resistant nephrotic syndrome and/or focal segmental glomerulosclerosis patients of different African ancestries. Nephrology Dialysis Transplantation, 2019, 34, 1885-1893.	0.7	12
98	Nephronophthisis in Young Adults Phenocopying Thrombotic Microangiopathy and Severe Nephrosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 615-617.	4.5	12
99	Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity. PLoS ONE, 2021, 16, e0252026.	2.5	12
100	Spondyloarthritis-Associated IgA Nephropathy. Kidney International Reports, 2020, 5, 813-820.	0.8	12
101	Successful Treatment of Acute Thrombotic Microangiopathy by Eculizumab After Combined Lung and Kidney Transplantation. Transplantation, 2013, 96, e58-e59.	1.0	11
102	ANCA-Negative Pauci-immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification. American Journal of Kidney Diseases, 2022, 79, 56-68.e1.	1.9	11
103	Effectiveness of a †do not interrupt†vest intervention to reduce medication errors during medication administration: a multicenter cluster randomized controlled trial. BMC Nursing, 2021, 20, 153.	2.5	11
104	ANCA-associated diseases and lung carcinomas: a five-case series. Clinical Nephrology, 2014, 81, 132-137.	0.7	11
105	New insights on IgA vasculitis with underlying solid tumor: a nationwide French study of 30 patients. Clinical Rheumatology, 2021, 40, 1933-1940.	2.2	10
106	Molecular Signatures of Kidney Antibody–Secreting Cells in Lupus Patients With Active Nephritis Upon Immunosuppressive Therapy. Arthritis and Rheumatology, 2021, 73, 1461-1466.	5.6	10
107	Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30â€∫months post-transplant. Clinical Transplantation, 2007, 21, 295-300.	1.6	9
108	Podocytes and Proteinuria in ANCA-Associated Glomerulonephritis: A Case-Control Study. Frontiers in Immunology, 2019, 10, 1405.	4.8	9

#	Article	IF	CITATIONS
109	A urinary cause of coma. Journal of Neurology, 2011, 258, 941-943.	3.6	8
110	From arterial stiffness to kidney graft microvasculature: Mortality and graft survival within a cohort of 220 kidney transplant recipients. PLoS ONE, 2018, 13, e0195928.	2.5	8
111	Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry. Arthritis and Rheumatology, 2021, 73, 641-650.	5.6	8
112	Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. Kidney International Reports, 2021, 6, 746-754.	0.8	8
113	Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. Rheumatology, 2022, 61, 2464-2471.	1.9	8
114	Nephrotoxicity Associated With Niraparib. American Journal of Kidney Diseases, 2020, 76, 898-900.	1.9	8
115	Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1665-1675.	4.5	8
116	Patients of 75 years and over with ANCAâ€associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study. Journal of Internal Medicine, 2021, , .	6.0	8
117	Cryoglobulin-Induced Cardiomyopathy. Journal of the American College of Cardiology, 2010, 55, e13.	2.8	7
118	Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury. Pharmacoepidemiology and Drug Safety, 2019, 28, 1583-1590.	1.9	7
119	Kidney transplantation improves the clinical outcomes of Acute Intermittent Porphyria. Molecular Genetics and Metabolism, 2020, 131, 259-266.	1.1	7
120	Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology, 2020, 59, 2970-2975.	1.9	7
121	The impact of interventions by pharmacists collected in a computerised physician order entry context: a prospective observational study with a 10-year reassessment. Swiss Medical Weekly, 2019, 149, w20015.	1.6	7
122	Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series. American Journal of Kidney Diseases, 2022, 80, 341-352.	1.9	7
123	Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis. Journal of Autoimmunity, 2016, 72, 57-64.	6.5	6
124	Extreme hypomagnesemia: characteristics of 119 consecutive inpatients. Internal and Emergency Medicine, $2018,13,1201\text{-}1209$.	2.0	6
125	Less arterial stiffness in kidney transplant recipients than chronic kidney disease patients matched for renal function. CKJ: Clinical Kidney Journal, 2021, 14, 1244-1254.	2.9	6
126	The urinary metabolome of chronic kidney disease. Kidney International, 2014, 85, 1239-1240.	5.2	5

#	Article	IF	CITATIONS
127	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. Frontiers in Immunology, 2021, 12, 701273.	4.8	5
128	Baroreflex sensitivity after kidney transplantation: arterial or neural improvement?. Nephrology Dialysis Transplantation, 2013, 28, 2401-2403.	0.7	4
129	Hyponatremia and Mortality in Patients With Cancer: The Devil Is in the Details. American Journal of Kidney Diseases, 2012, 59, 168-169.	1.9	3
130	Cholesterol Crystal Embolization after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2019, 381, 655-655.	27.0	3
131	Outcomes of Older Patients (â%¥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients. Journal of Clinical Medicine, 2019, 8, 298.	2.4	3
132	Lymphomas with kidney involvement: the French multicenter retrospective LyKID study. Leukemia and Lymphoma, 2020, 61, 887-895.	1.3	3
133	Natural Killer Cell Large Granular Lymphocyte Leukemia-Induced Glomerulonephritis. Kidney International Reports, 2021, 6, 1174-1177.	0.8	3
134	L39. Fulminant anca vasculitis. Presse Medicale, 2013, 42, 607-609.	1.9	2
135	Acute interstitial nephritis: aetiology and management. Nephrology Dialysis Transplantation, 2021, 36, 1799-1802.	0.7	2
136	Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E–mutated colorectal cancer. European Journal of Cancer, 2021, 147, 60-62.	2.8	2
137	French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis. Presse Medicale, 2022, 51, 104107.	1.9	2
138	Rein et lupus : données récentes. Revue Du Rhumatisme (Edition Francaise), 2005, 72, 162-167.	0.0	1
139	Type III Cryoglobulinemia Complicated by Renal Cortical Necrosis. American Journal of Kidney Diseases, 2005, 45, e79-e81.	1.9	1
140	Systemic Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1912-1915.	4.5	1
141	Atteintes rénales dans les spondyloarthrites. Revue Du Rhumatisme Monographies, 2015, 82, 22-26.	0.0	1
142	355.â€fFACTORS PREDICTING SEVERE INFECTIONS IN PATIENTS WITH SYSTEMIC NECROTIZING VASCULITIDES BASED ON DATA FROM 733 PATIENTS ENROLLED IN RANDOMIZED–CONTROLLED TRIALS. Rheumatology, 2019, 58, .	1.9	1
143	B-cell treatment in ANCA-associated vasculitis. Rheumatology, 2020, 59, iii68-iii73.	1.9	1
144	Epsteinâ€Barr virusâ€associated smooth muscle tumor in a kidney transplant recipient: A caseâ€report and review of the literature. Transplant Infectious Disease, 2021, 23, e13456.	1.7	1

#	Article	IF	CITATIONS
145	Quiz Page April 2016. American Journal of Kidney Diseases, 2016, 67, A17-A19.	1.9	0
146	The Case A man with hypertension, respiratory distress, and rapidly progressive renal failure. Kidney International, 2016, 89, 509-510.	5.2	0
147	255.â€fRENAL INVOLVEMENT IN EGPA: A MULTICENTRE RETROSPECTIVE STUDY OF 63 CASES. Rheumatology, 2019, 58, .	1.9	0
148	Local miscommunications between glomerular cells as potential therapeutic targets for crescentic glomerulonephritides. Nephrologie Et Therapeutique, 2019, 15, S1-S5.	0.5	0
149	THU0211â€EVOLUTION OF KIDNEY ANTIBODY SECRETING CELLS MOLECULAR SIGNATURE IN LUPUS PATIENTS WITH ACTIVE NEPHRITIS UPON IMMUNOSUPPRESSIVE THERAPY. , 2019, , .		0
150	O19â€Evolution of kidney antibody secreting cells molecular signature in lupus patients with active nephritis upon immunosuppressive therapy. , 2020, , .		0
151	Glomerulonephritis with non-Randall-type, non-cryoglobulinemic monoclonal immunoglobulin G deposits [PGNMID and ITG]. CKJ: Clinical Kidney Journal, 0, , .	2.9	O